Affiliation:
1. Bekhterev National Medical Research Center (NMRC) of Psychiatry and Neurology
Abstract
Purpose.To analyze the results of classical and modern studies reflecting the pathophysiological mechanisms of antipsychotic-induced tardive dyskinesia.Materials and methods. We searched for full-text publications in Russian and English in the databases of E-Library, PubMed, Web of Science and Springer published over the past decade, using keywords (tardive dyskinesia (TD), drug-induced tardive dyskinesia, antipsychotics (AP), neuroleptics, typical antipsychotics, atypical antipsychotics, pathophysiology, etiology and combinations of these words). In addition, the review included earlier publications of historical interest.Results. The lecture proposed theories of development of AP-induced TD, examining its effect on dopaminergic receptors, dopaminergic neurons, neurons of the basal ganglia, and other theories: activation of estrogen receptors, disorders of melatonin metabolism, disorders of the endogenous opioid system, oxidative stress with predominant oxidation processes, blockade of 5-HT2-receptors, a decrease in the pyridoxine level, genetic predisposition, interaction of AP with the brain trace element – iron, carbonyl stress and immune inflammation and the role of the neurotrophic factor.Conclusion. The disclosure of the mechanisms of AP-induced TD will allow the development of a strategy for personalized prevention and therapy of the considered neurological complication of the AP-therapy for schizophrenia in real clinical practice.
Publisher
Siberian State Medical University
Reference69 articles.
1. Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Publ., 2013.
2. Cornett E.M., Novitch M., Kaye A.D., Kata V., Kaye A.M. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017; 17 (2): 162–174. PubMed PMID: 28638290 DOI: 10.1043/TOJ-16-0108.
3. Khublarova L.A., Zakharov D.V., Mikhaylov V.A. Stratification of the risk of developing tardive drug-induced complications. Review of Psychiatry and Neurology. 2017; 4: 111–114 (in Russ.).
4. Khublarova L.A., Zakharov D.V., Mikhaylov V.A. Dynamics of quality of life indicators in patients with tardive neuroleptic dyskinesias in the process of botulinum therapy. Review of Psychiatry and Neurology. 2016; 4; 86–91 (in Russ.).
5. Kornetova E.G., Semke A.V., Dmitrieva E.G., Borodyuk Yu.N., Boyko A.S. Clinical and social risk factors of tardive dyskinesia in patients with schizophrenia during antipsychotic treatment. Bulletin of Siberian Medicine. 2015; 14 (1): 32–39 (in Russ.). DOI: 10.20538/1682-0363-2015-1-32-39.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献